| Identification | Back Directory | [Name]
L-Leucine, L-tyrosylglycyl-L-arginyl-L-lysyl-L-lysyl-L-arginyl-L-arginyl-L-glutaminyl-L-arginyl-L-arginyl-L-arginyl-L-alanyl-L-arginyl-L-seryl-L-arginyl-L-leucyl-L-lysyl-L-α-glutamyl-L-leucyl-L-arginylglycyl-L-valyl-L-prolyl-L-arginylglycyl- | [CAS]
1505463-57-9 | [Synonyms]
L-Leucine, L-tyrosylglycyl-L-arginyl-L-lysyl-L-lysyl-L-arginyl-L-arginyl-L-glutaminyl-L-arginyl-L-arginyl-L-arginyl-L-alanyl-L-arginyl-L-seryl-L-arginyl-L-leucyl-L-lysyl-L-α-glutamyl-L-leucyl-L-arginylglycyl-L-valyl-L-prolyl-L-arginylglycyl- | [Molecular Formula]
C137H250N60O32 | [MOL File]
1505463-57-9.mol | [Molecular Weight]
3249.84 |
| Chemical Properties | Back Directory | [density ]
1.51±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted) | [Sequence]
Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-Ala-Arg-Ser-Arg-Leu-Lys-Glu-Leu-Arg-Gly-Val-Pro-Arg-Gly-Leu |
| Hazard Information | Back Directory | [Uses]
TAT-CBD3A6K, is a modified TAT-CBD3 peptide. TAT-CBD3A6K reduces T- and R-type voltage-dependent calcium currents in dorsal root ganglion (DRG) neurons. TAT-CBD3A6K shows anti-nociceptive effects in a model of AIDS-induced peripheral neuropathy by preventing CRMP-2-mediated enhancement of T- and R-type calcium channel function[1][2]. | [References]
[1] Piekarz AD, et al. CRMP-2 peptide mediated decrease of high and low voltage-activated calcium channels, attenuation of nociceptor excitability, and anti-nociception in a model of AIDS therapy-induced painful peripheral neuropathy. Mol Pain. 2012 Jul 24;8:54. DOI:10.1186/1744-8069-8-54
[2] Meloni BP, et al. Neuroprotective peptides fused to arginine-rich cell penetrating peptides: Neuroprotective mechanism likely mediated by peptide endocytic properties. Pharmacol Ther. 2015 Sep;153:36-54. DOI:10.1016/j.pharmthera.2015.06.002 |
|
|